Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trialChristoph Röllig, Gerhard Ehninger, Hubert Serve et al.|The Lancet Oncology|2015Cited by 402
Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trialChristoph Röllig, Hubert Serve, Richard Noppeney et al.|Leukemia|2021Cited by 58
Severe pernicious anemia with distinct cytogenetic and flow cytometric aberrations mimicking myelodysplastic syndromeStefani Parmentier, Uwe Platzbecker, Joern Meinel et al.|Annals of Hematology|2012Cited by 28
The Addition of Sorafenib to Standard AML Treatment Results in a Substantial Reduction in Relapse Risk and Improved Survival. Updated Results from Long-Term Follow-up of the Randomized-Controlled Soraml TrialChristoph Röllig, Gerhard Ehninger, Hubert Serve et al.|Blood|2017Cited by 21
A Rapid Flow Cytometric Method for the Detection of NPM1 Mutated Patients with Acute Myeloid Leukemia (AML).Uta Oelschlaegel, Christian Thiede, Sina Koch et al.|Blood|2008Cited by 6